Author: Yousefi Dehbidi, Maryam; Goodarzi, Nima; Azhdari, Mohammad H.; Doroudian, Mohammad
Title: Mesenchymal stem cells and their derived exosomes to combat Covid–19 Cord-id: wxwmdoa6 Document date: 2021_8_7
ID: wxwmdoa6
Snippet: Severe acute respiratory syndrome coronavirus 2 (SARSâ€CoVâ€2) is causing an ongoing pandemic of coronavirus disease 2019 (Covidâ€19). Effective therapies are required for the treatment of patients with severe stages of the disease. Mesenchymal stem cells (MSCs) have been evaluated in numerous clinical trials, but present challenges, such as carcinogenic risk and special storage conditions, coupled with insufficient data about their mechanism of action. The majority of unique properties of MS
Document: Severe acute respiratory syndrome coronavirus 2 (SARSâ€CoVâ€2) is causing an ongoing pandemic of coronavirus disease 2019 (Covidâ€19). Effective therapies are required for the treatment of patients with severe stages of the disease. Mesenchymal stem cells (MSCs) have been evaluated in numerous clinical trials, but present challenges, such as carcinogenic risk and special storage conditions, coupled with insufficient data about their mechanism of action. The majority of unique properties of MSCs are related to their paracrine activity and especially to their exosomes. The impact of MSCsâ€derived exosomes (MSCâ€Es) on complications of Covidâ€19 has been investigated in several studies. MSCâ€Es may improve some complications of Covidâ€19 such as cytokine storm, acute respiratory distress syndrome (ARDS) and acute lung injury (ALI). Additionally, these exosomes can be evaluated as an applicable nanoâ€size carrier for antiviral therapeutic agents. Herein, we consider several potential applications of MSCs and their derived exosomes in the treatment of Covidâ€19.
Search related documents:
Co phrase search for related documents- accessory protein and acute infection: 1, 2, 3, 4, 5, 6
- accessory protein and acute lung injury: 1
- accessory protein and lung addition: 1
- accessory protein and lung damage: 1
- accessory protein and lung disease: 1, 2, 3
- accessory protein and lung injury: 1, 2
- accessory structural and acute infection: 1, 2
- accessory structural and adaptive immune response: 1
- accessory structural and lung injury: 1
- acute ards respiratory distress syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute ards respiratory distress syndrome and long covid: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31
- acute ards respiratory distress syndrome and long covid syndrome: 1, 2
- acute ards respiratory distress syndrome and long covid syndrome term: 1
- acute ards respiratory distress syndrome and low immunogenicity: 1, 2, 3
- acute ards respiratory distress syndrome and low survival: 1, 2, 3, 4, 5, 6, 7, 8
- acute ards respiratory distress syndrome and low tumorigenicity: 1
- acute ards respiratory distress syndrome and lung addition: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acute ards respiratory distress syndrome and lung brain: 1, 2, 3, 4, 5, 6, 7, 8
- acute ards respiratory distress syndrome and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
Co phrase search for related documents, hyperlinks ordered by date